MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients
How to Cite
OrthoEvidence. MTP-PE added to chemotherapy did not improve outcomes in metastatic osteosarcoma patients. ACE Report. 2013;2(7):612. Available from: https://myorthoevidene.com/AceReport/Report/5098
Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology GroupCancer. 2009 Nov 15;115(22):5339-48. doi: 10.1002/cncr.24566
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
91 patients with metastatic osteosarcoma were randomized to receive a 3-drug treatment of chemotherapy (cisplatin, doxorubicin, and high-dose methotrexate) with or without ifosfamide. Within each group patients were further randomized to either receive liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) or not to determine whether the addition of liposomal MTP-PE to chemotherapy was eff...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE